Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Lung Inflammation Clear all
Completed No phase listed Observational

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

NCT04401449
View directory record Official record
Conditions
Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 26, 2026, 7:32 AM EDT
Completed No phase listed Observational

Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure

NCT03225807
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency, Respiratory Distress Syndrome, Shock Lung, Severe Acute Respiratory Syndrome
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Immulina TM Supplements With PASC Patients

NCT05524532
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
8
States / cities
Honolulu, Hawaii • Baton Rouge, Louisiana • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jun 26, 2026, 7:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jun 26, 2026, 7:32 AM EDT
Enrolling by invitation Phase 2 Interventional

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

NCT05350774
View directory record Official record
Conditions
Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions
IV normal saline, IV immunoglobulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis

NCT05930418
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Sepsis, Cardiovascular Shock
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 2 Interventional

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

NCT00879606
View directory record Official record
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
ALT-836, Placebo
Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jun 26, 2026, 7:32 AM EDT
Not yet recruiting No phase listed Observational

Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1

NCT07249762
View directory record Official record
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 26, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jun 26, 2026, 7:32 AM EDT
Completed No phase listed Observational

Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

NCT00980915
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Jun 26, 2026, 7:32 AM EDT
Active, not recruiting Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

NCT06940141
View directory record Official record
Conditions
Asthma Acute
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Palo Alto, California • Valencia, California • Wilmington, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Hospitalization at Home: The Acute Care Home Hospital Program for Adults

NCT02864420
View directory record Official record
Conditions
Pneumonia, Heart Failure, Cellulitis, Urinary Tract Infections
Interventions
Home hospitalization, Inpatient Hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

NCT00004494
View directory record Official record
Conditions
Sepsis, Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
Interventions
vasoactive intestinal peptide
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Northport, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Jun 26, 2026, 7:32 AM EDT
Terminated No phase listed Observational

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

NCT03557749
View directory record Official record
Conditions
Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Recurrent Malignancy, Cytokine Release Syndrome, Allogenic Related Donors, Cell Therapy/Immunotherapy Patients
Interventions
Blood Sample, Stool Sample, Urine Sample, Bronchoalveolar Lavage (BAL) fluid, Gastrointestinal biopsy x 2-4, Skin biopsy, Skin, mouth, and/or ocular swab, Apheresis Product, Final cellular product
Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

NCT01739933
View directory record Official record
Conditions
Sepsis, Delirium, Impaired Cognition
Interventions
Dexmedetomidine, Propofol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
11
States / cities
San Francisco, California • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jun 26, 2026, 7:32 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jun 26, 2026, 7:32 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air

NCT05680831
View directory record Official record
Conditions
Lung Injury, Acute, Symptoms and Signs, Neutrophilia Acute
Interventions
0.070 ppm ozone concentration, Clean air (0.0 ppm ozone)
Biological
Lead sponsor
Martin W. Case
Federal
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Jun 26, 2026, 7:32 AM EDT
Completed No phase listed Observational

The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)

NCT03654352
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Sturgill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jun 26, 2026, 7:32 AM EDT
Completed No phase listed Observational

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

NCT04706533
View directory record Official record
Conditions
Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
Interventions
Biomarkers of inflammation
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Multimodal Investigation of Post COVID-19 in Females

NCT05225220
View directory record Official record
Conditions
Post COVID-19, Cognitive Dysfunction
Interventions
Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)
Device
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jun 26, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jun 26, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jun 26, 2026, 7:32 AM EDT